Zeo ScientifiXZEOX 50 Quick Ratio is 0.83 as of Apr. 2026, which is 493% above its 10-year median of 0.14. GuruFocus rates ZEOX with a GF Score™ of 50/100 and a GF Value™ of $2.67 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, Zeo ScientifiX ranks worse than 84.18% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Zeo ScientifiX's quick ratio for the quarter that ended in Apr. 2026 was 0.83.
Zeo ScientifiX has a quick ratio of 0.83. It indicates that the company cannot currently fully pay back its current liabilities.
The historical rank and industry rank for Zeo ScientifiX's Quick Ratio or its related term are showing as below:
ZEOX'
s Quick Ratio Range Over the Past 10 Years
Min: 0.02 Med: 0.14 Max: 1.01
Current: 0.83
During the past 13 years, Zeo ScientifiX's highest Quick Ratio was 1.01. The lowest was 0.02. And the median was 0.14.
ZEOX's Quick Ratio is ranked worse than 84.18% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs ZEOX: 0.83
Zeo ScientifiX (OTCPK:ZEOX) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Zeo ScientifiX Quick Ratio Related Terms
Zeo ScientifiX Quick Ratio Historical Data
* Premium members only.
The historical data trend for Zeo ScientifiX's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Zeo ScientifiX's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zeo ScientifiX Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zeo ScientifiX's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Zeo ScientifiX's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Zeo ScientifiX's Quick Ratio for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zeo ScientifiX (ZEOX) has a Quick Ratio of 0.83 as of Apr. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Zeo ScientifiX and its competitors. This is 493% above median its historical median of 0.14. Over the past decade, Zeo ScientifiX's Quick Ratio has ranged from 0.02 to 1.01. According to the industry distribution chart, Zeo ScientifiX ranks #1192 out of 1416 companies in the Biotechnology industry, placing it in the top 84.2%.
Is Zeo ScientifiX's Quick Ratio too high?
Zeo ScientifiX's current Quick Ratio of 0.83 is 493% above median its 10-year median of 0.14. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 1.01. The Biotechnology industry median Quick Ratio is 3.60. Zeo ScientifiX's value of 0.83 is 76.9% below this industry median. Based on the distribution chart, Zeo ScientifiX ranks #1192 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zeo ScientifiX has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Zeo ScientifiX's Quick Ratio compare to LNAI and GDTC?
According to the Biotechnology industry distribution chart, Zeo ScientifiX ranks #1192 out of 1416 companies for Quick Ratio. This places Zeo ScientifiX in the lower half of its industry. The industry median Quick Ratio is 3.60. Zeo ScientifiX's value of 0.83 is 76.9% below this benchmark. Historically, Zeo ScientifiX's own Quick Ratio has ranged from 0.02 to 1.01 over the past decade. While the company's 10-year median is 0.14 vs. the industry median of 3.60, Zeo ScientifiX has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zeo ScientifiX's current Quick Ratio of 0.83 is 76.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Zeo ScientifiX and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zeo ScientifiX's current Quick Ratio is 0.83, which is 493% above median its own 10-year median of 0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zeo ScientifiX stock overvalued right now?
Based on GuruFocus' analysis, Zeo ScientifiX (ZEOX) is currently considered Possible Value Trap. The stock's GF Value™ is $2.67, compared to a current price of $1.75 — trading 34.5% below its estimated fair value. The current Quick Ratio is 0.83, which is 493% above median its 10-year median of 0.14 and 76.9% below the Biotechnology industry median of 3.60. Zeo ScientifiX's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Zeo ScientifiX (ZEOX), the current Quick Ratio is 0.83 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zeo ScientifiX (ZEOX) Overvalued in 2026?
Based on GuruFocus' analysis, Zeo ScientifiX stock appears to be undervalued.
The current stock price of $1.75 is trading 34.5% below its estimated GF Value™ of $2.67.
GuruFocus considers Zeo ScientifiX to be Possible Value Trap.
Key valuation signals for ZEOX:
Quick Ratio: 0.83 (493% above median its 10-year median of 0.14)
GF Value™: $2.67 vs. price of $1.75 (34.5% below fair value)
Industry Position: 76.9% below the Biotechnology median (#1192 of 1416)
No single metric tells the full story. See the ZEOX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zeo ScientifiX Inc is a clinical-stage biopharmaceutical company located inside Nova Southeastern University's Collaborative Center for Research in Davie, Florida. The Company is a clinical-stage biopharmaceutical company principally focusing on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicine. The Company's proprietary products, including Zofin, are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, proteins and cell secreted nanoparticles and Patient Pure X (PPX ), an autologous biologic containing a nanoparticle fraction that is precipitated from a patient's own peripheral blood (RAAM Products).
50GF Score
Get the complete analysis for ZEOX
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZEOX has been successfully added to your 
